Também conhecido como
EGFR [Her-1]
Nome formal
Epidermal Growth Factor Receptor
Este artigo foi revisto pela última vez em
Este artigo foi modificado pela última vez em 29 de Setembro de 2017.
De relance
Por que fazer este exame?

To determine whether a solid tumor, such as of the lung (non small cell), head and neck, colon, pancreas, or breast, is positive for EGFR, which helps to guide treatment and determine prognosis

Quando fazer este exame?

When you have been diagnosed with certain invasive cancers and your doctor wants to determine whether EGFR is being over-expressed in the tumor


A sample of tumor tissue obtained during a biopsy

É necessária alguma preparação?


O que está sendo pesquisado?

EGFR is one of a family of cell membrane receptors that help regulate cell growth, division, survival and death. In a variety of cancers, there is an increased amount of EGFR present in the tumor tissue. This can be due to amplification and over-expression of the receptor that leads to excessive signaling for growth. Tumors that have increased EGFR protein tend to grow more aggressively, are more likely to metastasize, and are more resistant to standard chemotherapies. Patients with these tumors tend to have a poorer outcome. Consequently, targeting the EGFR is a valuable molecular approach in cancer therapy. EGFR-specific antibodies that bind to the receptor and prevent signaling are used to treat some of the malignancies.

There are two main ways to test tumors for amplified or over-expressed EGFR: one method measures the amount of EGFR protein present; the other looks at the genetic level for gene amplification - it evaluates the number of copies of the gene present.

How is the sample collected for testing?

A sample of cancer tissue is obtained by doing a biopsy. The biopsy procedure required depends on the organ(s) affected.

Is any test preparation needed to ensure the quality of the sample?

No test preparation is needed.

Accordion Title
Perguntas frequentes
  • Como o exame é usado?

    EGFR testing may be ordered on those diagnosed with cancer, such as colon cancer, non-small cell lung cancer, glioblastoma (a type of brain cancer), and cancer of the head and neck, breast, or pancreas. It is primarily used to help guide treatment of some cancers and to determine whether a patient can benefit from targeted therapy with an antibody to EGFR. Several drugs called “EGFR inhibitors” have been developed to target the action of EGFR. If a person’s tumor has increased amounts of EGFR, then an EGFR inhibitor may be considered as part of the cancer treatment.

    The test may also be used as a prognostic marker to help determine how aggressive a cancer is likely to be.

  • Quando o exame é pedido?

    EGFR testing may be ordered as part of an initial workup of particular cancers or performed on those with certain cancers that are not responding to chemotherapy. It may be done at any time, but it requires a sample of the tumor tissue. If a sample is available from a previous biopsy, it can be done on that sample.

  • O que significa o resultado do exame?

    EGFR testing is not diagnostic, but it helps the doctor understand more about the tumor’s characteristics, evaluate a patient’s overall prognosis, and determine treatment options. If testing using either of the methods is positive, then the patient is more likely to have a tumor that is aggressive and resistant to chemotherapy.

  • Há mais alguma coisa que eu devo saber?

    EGFR blocking agents are routinely being used for treatment of colon cancer and are used with some head and neck cancers. Clinical trials are ongoing to study their effectiveness in the treatment of non small cell lung cancer, and their use may soon be considered for breast cancer treatment.

    The utility of these EGFR inhibitors and their correlation to EGFR results in different types of cancers has yet to be fully established. The role of testing for certain EGFR gene mutations and the mutations’ affect on a patient’s responsiveness to treatment is also being explored.

    EGFR testing is not available in every laboratory. If your doctor sends your sample to a reference laboratory, the results may take a few weeks to return.

  • Is there a blood test for EGFR?

    Not yet. Researchers have been able to detect excess EGFR, produced by a tumor, in the bloodstream but a clinically useful test is not yet available.

  • What is the difference between EGFR (Her-1) and Her-2/neu?

    EGFR and Her-2/neu are both members of the same family of cell membrane receptors. They are both measured in tumor tissue and evaluated for over-expression or amplification. When either EGFR or Her-2/neu is significantly increased in a cancer, it indicates a more aggressive tumor and a poorer patient prognosis. The primary differences between EGFR and Her-2/neu are that they are ordered to help evaluate different types of cancer and that the drugs that have been developed to target them are specific for that particular receptor, EGFR or Her-2/neu. Her-2/neu  is used for diagnosis and prognosis of breast cancer.

Páginas relacionadas

Neste site

Exames relacionados: Her-2/neu

Were you looking for Estimated Glomerular Filtration Rate, also known as eGFR?

Conditions: Breast cancer, Colon cancer, Pancreatic cancer

Em outros sites da Internet

American Cancer Society: Monoclonal Antibodies

Fontes do artigo

NOTA: Este artigo se baseia em pesquisas que incluíram as fontes citadas e a experiência coletiva de Lab Tests Online Conselho de Revisão Editorial. Este artigo é submetido a revisões periódicas do Conselho Editorial, e pode ser atualizado como resultado dessas revisões. Novas fontes citadas serão adicionadas à lista e distinguidas das fontes originais usadas.


Sources Used in Most Recent Review

Kuriyan, J. (2006 June 16). Researchers Learn How Epidermal Growth Factor Receptor Is Activated. Howard Hughes Medical Institute [On-line information]. Available online at http://www.hhmi.org/news/kuriyan20060615.html through http://www.hhmi.org. Accessed on 7-30-08.

American Cancer Society [On-line information]. (2007 May 14, Revised). Detailed Guide: Laryngeal and Hypopharyngeal Cancer. What's New in Laryngeal and Hypopharyngeal Cancer Research and Treatment? Available online through http://www.cancer.org. Accessed on 7-30-08.

Chu, E. et. al. (2007 July 25). Expanding Scientific Evidence for Epidermal Growth Factor Receptor-Directed Therapy in Colorectal Cancer and Squamous Cell Carcinoma of the Head and Neck CME. Medscape Today [On-line information]. Available online at http://www.medscape.com/viewprogram/7463 through http://www.medscape.com. Accessed on 7-30-08.

Dacic, S. et. al. (2006 June 6). Significance of EGFR Protein Expression and Gene Amplification in Non-Small Cell Lung Carcinoma. Medscape from Am J Clin Pathol. 2006;125(6):860-865 [On-line information]. Available online at http://www.medscape.com/viewarticle/532262 through http://www.medscape.com. Accessed on 7-30-08.

Grody, W. (2007 January 30). ASCP 2006: Applications of Molecular Methods in Surgical Pathology CME/CMLE. Medscape [On-line information]. Available online at http://www.medscape.com/viewarticle/551100 through http://www.medscape.com. Accessed on 7-30-08.

Sources Used in Previous Reviews

Thomas, Clayton L., Editor (1997). Taber’s Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby’s Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

(2004 April). EGFR by FISH. ARUP Technical Bulletin [On-line information]. PDF available for dowload at http://www.arup-lab.com/media/pdf/testing/tech_bulletins/egfr_apr04.pdf through http://www.arup-lab.com.

(© 2004). EGFR by FISH. ARUP's Guide to Clinical Laboratory Testing [On-line information]. Available online at http://www.aruplab.com/guides/clt/tests/clt_a213.jsp#3635067 through http://www.aruplab.com.

Check, W. (2004 January). New school of FISH: solid tumor testing. CAP Cover Story [On-line journal article]. Available online at http://www.cap.org/apps/docs/cap_today/cover_stories/0104NewSchoolOfFISH.html through http://www.cap.org.

(2004). Epidermal Growth Factor Receptor Assay, Iressa (Gefitinib) responsiveness in lung cancer, EGFR Gene Analysis. Clinical Molecular Diagnostic Laboratory [On-line information]. Available Online at http://www.cityofhope.org/cmdl/EGFR.asp through http://www.cityofhope.org.

(© 2003). Epidermal Growth Factor Receptor (EGFR), Breast Cancer. LabCorp [On-line test information]. Available Online at http://www.labcorp.com/datasets/labcorp/html/chapter/ through http://www.labcorp.com.

(2004 April 29). Discovery Promises Better Use of Iressa for Lung Cancer. American Cancer Society, ACS News Center [On-line article]. Available online at http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Discovery_Promises_Better_Use_of_Iressa_for_Lung_Cancer.asp through http://www.cancer.org.

Ang, K. et. al. (2002 December 15). Impact of Epidermal Growth Factor Receptor Expression on Survival and Pattern of Relapse in Patients with Advanced Head and Neck Carcinoma. Cancer Research 62, 7350-7356 [On-line journal]. Available Online at http://cancerres.aacrjournals.org/cgi/content/full/62/24/7350 through http://cancerres.aacrjournals.org.

(2004 April 29). Presence of Gene Mutation Tightly Linked to Drug Effectiveness in Lung Cancer. National Cancer Institute [On-line news]. Available Online at http://www.cancer.gov/newscenter/pressreleases/IressaMutation through http://www.cancer.gov.

Billingsley, J. (2003 December 6). New Clue to Breast Cancer Mortality, Growth factor identified with poorer outcomes in patients. Henry Ford Health System [On-line news]. Available Online at http://www.henryfordhealth.org/110736.cfm through http://www.henryfordhealth.org.

Langreth, R. (2004 April 29). Gene Predicts Cancer Drug Effectiveness. Forbes.com Pharmaceuticals [On-line article]. Available Online at http://www.forbes.com/2004/04/29/cx_rl_0429cancer_print.html through http://www.forbes.com.

(2003). Epidermal Growth Factor Receptor Status in Breast Cancer Metastases to the Central Nervous System - Comparison With HER-2/neu Status. CAP [On-line Abstracts From the College of American Pathologists 2003 Annual Meeting (CAP '03)]. Available Online at http://www.cap.org/apps/docs/archives_pathology_lab_med/this_month.html through http://www.cap.org.

Weaver, C. and Maxon, J. (1998- 2004). Targeting Epidermal Growth Factor Receptor Pathways. CancerConsultants.com Current Topics in Oncology [On-line information]. Available online at http://www.411cancer.com/syndication/veContent.jsp?ArticleID=egfr_02&ArticleTypeID=CTON through http://www.411cancer.com.